Latest filings (excl ownership)
SEC STAFF ACTION
SEC staff action: Order
1 Sep 22
25-NSE
Exchange delisting
29 Apr 20
8-K
Entry into a Material Definitive Agreement
29 Apr 20
8-K
Other Events
3 Apr 20
8-K
Changes in Registrant's Certifying Accountant
31 Mar 20
8-K
Sophiris Bio Announces Nasdaq Delisting
11 Mar 20
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
27 Jan 20
8-K
Departure of Directors or Certain Officers
23 Dec 19
8-K
Departure of Directors or Certain Officers
13 Dec 19
8-K
Departure of Directors or Certain Officers
13 Dec 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9 Dec 19
S-1
IPO registration
13 Nov 19
10-Q
2019 Q3
Quarterly report
8 Nov 19
8-K
Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
7 Nov 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Oct 19
8-K/A
Submission of Matters to a Vote of Security Holders
8 Oct 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Sep 19
D
$5.07M in options / securities to be acquired, sold $5.07M, 1 investor
6 Sep 19
8-K
Unregistered Sales of Equity Securities
30 Aug 19
8-K
Sophiris Bio Announces $4.0 Million Registered Direct Offering
27 Aug 19
424B5
Prospectus supplement for primary offering
27 Aug 19
10-Q
2019 Q2
Quarterly report
9 Aug 19
8-K
Sophiris Bio Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
9 Aug 19
8-K
Submission of Matters to a Vote of Security Holders
28 Jun 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 Jun 19
10-Q
2019 Q1
Quarterly report
9 May 19
8-K
Sophiris Bio Reports First Quarter 2019 Financial Results
9 May 19
DEFA14A
Additional proxy soliciting materials
30 Apr 19
DEF 14A
Definitive proxy
30 Apr 19
10-K
2018 FY
Annual report
13 Mar 19
8-K
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
13 Mar 19
8-K
Departure of Directors or Certain Officers
3 Jan 19
CT ORDER
Confidential treatment order
21 Dec 18
8-K
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
17 Dec 18
424B5
Prospectus supplement for primary offering
7 Dec 18
8-K
Entry into a Material Definitive Agreement
7 Dec 18
10-Q
2018 Q3
Quarterly report
13 Nov 18
8-K
Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
13 Nov 18
8-K
Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial
30 Aug 18
10-Q
2018 Q2
Quarterly report
14 Aug 18
Latest ownership filings
SC 13G/A
Sophiris Bio Inc.
14 Feb 20
4
Peter T Slover
23 Dec 19
4
RANDALL E WOODS
23 Dec 19
4
ALLISON HULME
23 Dec 19
SC 13G
Sophiris Bio Inc.
6 Sep 19
4
GERALD T PROEHL
28 Jun 19
4
JAMES L HEPPELL
28 Jun 19
4
John Geltosky
28 Jun 19
4
Lars Ekman
28 Jun 19
4
Peter T Slover
3 Jan 19
4
ALLISON HULME
3 Jan 19
4
RANDALL E WOODS
3 Jan 19
4/A
RANDALL E WOODS
20 Sep 18
4
RANDALL E WOODS
20 Sep 18
4
GERALD T PROEHL
28 Jun 18
4
JAMES L HEPPELL
28 Jun 18
4
John Geltosky
28 Jun 18
4
Lars Ekman
28 Jun 18
4
ALLISON HULME
8 Dec 17
4
Peter T Slover
8 Dec 17
4
RANDALL E WOODS
8 Dec 17
4
GERALD T PROEHL
1 Jun 17
4
Lars Ekman
1 Jun 17
4
John Geltosky
1 Jun 17
4
JAMES L HEPPELL
1 Jun 17
SC 13G/A
Sophiris Bio Inc.
14 Feb 17
SC 13G/A
Sophiris Bio Inc.
14 Feb 17
SC 13G/A
Sophiris Bio Inc.
10 Feb 17
3/A
JAMES L HEPPELL
8 Feb 17
3/A
JAMES L HEPPELL
8 Feb 17
4/A
JAMES L HEPPELL
8 Feb 17
SC 13G/A
Sophiris Bio Inc.
30 Jan 17
SC 13G/A
Sophiris Bio Inc.
11 Jan 17
4
RANDALL E WOODS
9 Dec 16
4
Peter T Slover
9 Dec 16
4
ALLISON HULME
9 Dec 16
4
JAMES L HEPPELL
31 Oct 16
SC 13G
Sophiris Bio Inc.
26 Aug 16
SC 13G
Sophiris Bio Inc.
25 Aug 16
4
ALLISON HULME
1 Jun 16